Today: 22 July 2026
Browse Category

NYSE:LLY 28 September 2025 - 5 November 2025

For live price, interactive charts, financials and the latest market data, visit Google Finance.
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk’s Weight-Loss Drug Boom Hits a Wall – Wegovy Slowdown Sparks Stock Slump and Forecast Cut

Just a year ago, Novo Nordisk – buoyed by the meteoric success of its weight-loss injection Wegovy – briefly eclipsed all other European companies in market valuereuters.com. The Danish pharmaceutical giant enjoyed surging sales as Wegovy and its type-2 diabetes sibling Ozempic became global sensations, with millions seeking their dramatic weight-loss benefits. However, 2025 has seen a sharp reversal of fortune. A “slew of headwinds has shaken investor confidence” in Novo Nordisk’s once-dominant growth storystockanalysis.com. The company’s share price has plummeted nearly 50% year-to-date amid signs that demand growth is slowing and profitability is coming under pressurereuters.com.
5 November 2025
···
Eli Lilly Stock Pre-Market Preview: Will Obesity-Drug Boom Send LLY to New Highs? (Nov 3, 2025)

Eli Lilly Stock Pre-Market Preview: Will Obesity-Drug Boom Send LLY to New Highs? (Nov 3, 2025)

As of Oct. 31 close, Eli Lilly was around $862–864 Stockanalysis Marketbeat. That’s up ~9–10% from early October Nasdaq. Trading volumes have been heavy, and LLY remains near its 52-week high Marketbeat. MarketBeat notes LLY’s 50-day moving average is ~$780 Marketbeat, reflecting the recent surge. Institutional ownership is high and sentiment is bullish.
2 November 2025
·
Eli Lilly (LLY) Stock Soars on Weight-Loss Drug Boom – Can It Hit $1,000?

Eli Lilly (LLY) Stock Soars on Weight-Loss Drug Boom – Can It Hit $1,000?

Eli Lilly’s stock has moved sharply in recent weeks. After languishing around the mid-$700s in late September, the stock soared in early October. Between Sept. 29 and Oct. 1 it jumped over 9%, briefly touching the low $830s ts2.tech. Analysts noted this jump was fueled by a “perfect storm” of good news: better-than-expected trial results and anticipation of strong earnings. Trading volume was heavy, and by Oct. 23 shares were holding near $818 ts2.tech, about 6% higher on the year.
30 October 2025
·
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly Stock on Fire: GLP-1 Bonanza, Big Earnings & AI Pivot Drive Rally

Eli Lilly’s stock has been on a tear this year, driven by blockbuster drug sales and upbeat guidance. As of Oct. 29, 2025, LLY traded near $813.53investing.com. After hitting highs in the mid-$850s in early October, the shares have pulled back modestly. Trading volume and technical indicators suggest a consolidation phase after the recent rallyintellectia.aiintellectia.ai.
30 October 2025
···
2025’s Best-Performing Stock Market Is Up 35% – Here’s What’s Driving the Rally

2025’s Best-Performing Stock Market Is Up 35% – Here’s What’s Driving the Rally

Stock markets around the world are on fire heading into the final days of October 2025. Hong Kong’s Hang Seng Index – up about 34–35% so far this year – is the planet’s best-performing major index Advisorperspectives. After a brutal multi-year slump, Hong Kong’s market came roaring back thanks to ultra-cheap valuations and China’s post-pandemic stimulus. Investors flooded into undervalued Chinese tech and consumer stocks, driving a dramatic rebound. As a result, the Hang Seng has erased its losses from prior years and is flirting with three-year highs Dividendtitan Dividendtitan. “The market was clearly undervalued… confidence returned, money flowed in again,” one Hong Kong analyst noted of 2025’s turnaround Dividendtitan. A series of catalysts fueled the surge – from Beijing’s big economic stimulus packages to breakthroughs in Chinese AI technology and blockbuster movie releases energizing consumer sentiment Dividendtitan Dividendtitan. Even a mid-October trade scare barely dented the momentum – the Hang Seng Volatility Index spiked, but investors quickly bought the dip, betting that U.S.-China tensions would ease Reuters Reuters. As of this week, Hong Kong stocks remain on a tear, buoyed by renewed trade-deal hopes and expectations of further Chinese policy support. The Hang Seng’s resilience – up ~30%+ in
29 October 2025
···
Pharma Giants Converge in Frankfurt – Obesity Drug Boom & Tech Innovations Fuel $1.7 Trillion Industry Future

Pharma Giants Converge in Frankfurt – Obesity Drug Boom & Tech Innovations Fuel $1.7 Trillion Industry Future

Sources: CPHI Frankfurt event coveragecontractpharma.comgxpnews.net; GxP Newsgxpnews.netgxpnews.net; The Medicine Maker/Conexiantconexiant.comconexiant.com; GlobeNewswireglobenewswire.com; Evaluate Pharma forecastevaluate.comevaluate.com; Reutersreuters.com; TechStock² / TS2 Techts2.techts2.tech; TS2 Techts2.techts2.tech.
28 October 2025
····
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Stock Soars on Obesity-Drug Boom — Is $1,000 Next?

Eli Lilly has been on a tear in October 2025. After closing around $726 on Sept. 29, the stock surged more than 9% in the following days, briefly spiking to about $832 on Oct. 1ts2.techts2.tech. Trading volume was heavy and analysts pointed to a “perfect storm” of news – Eli Lilly’s weight-loss and Alzheimer’s drug advances were cited as key drivers. As one tech-stock analysis observed, traders noted “bullish options activity and growing excitement over Lilly’s weight-loss drugs and Alzheimer’s research” fueling the rallyts2.tech. By Oct. 23, LLY was trading near $818tradingview.com, solidly above its pre-September levels. Overall, the stock is up roughly 6% year-to-date, about matching the S&P 500 health-care indextradingview.com.
23 October 2025
··
Stocks to Buy Today (Oct. 22, 2025): Top Picks as Markets Near Record Highs

Stocks to Buy Today (Oct. 22, 2025): Top Picks as Markets Near Record Highs

Stocks are starting today on cautiously optimistic footing. Futures were little changed this morning after a batch of earnings delivered both relief and warnings. Netflix shocked investors with a rare earnings miss, sending its stock down ~6–7% in pre-market tradingreuters.com. And chipmaker Texas Instruments sank nearly 9% after issuing a bleak sales forecast, which in turn dragged down other semiconductor namesreuters.com. Those disappointments put a slight chill on Nasdaq futures. “We’re at a bit of a point of indecision, where nobody feels particularly strongly about anything,” noted Michael Green of Simplify Asset Management, observing that even earnings surprises aren’t moving markets much in this wait-and-see environmentreuters.com.
22 October 2025
···········
Beam Therapeutics Stock Soars on Gene-Editing Buzz – Analysts Project Big Upside

Beam Therapeutics Stock Soars on Gene-Editing Buzz – Analysts Project Big Upside

Beam Therapeutics’ stock surged on Monday, Oct. 20, extending a strong upward streak. By mid-afternoon the share price hit $30.35, up 16.8% for the dayfinviz.com. This marked BEAM’s highest price since early 2024 and a dramatic rebound from its summer lows. Traders point to a bullish “golden cross” pattern on Beam’s chart – the stock’s 50-day moving average recently rose above its 200-day averagefinviz.com, a technical signal often seen as confirmation of a positive trend reversal. Zacks noted that BEAM had rallied ~6.8% over the prior four weeks leading into this golden-cross eventfinviz.com, helping shift its Zacks Rank to #2. The sharp Monday jump may have been fueled by momentum traders reacting to these technicals and upbeat analyst commentary, as well as broader sector tailwinds.
20 October 2025
·····
Nasdaq’s Wild Week: Tech Titans Soar & Plunge as Volatility Spikes – What’s Next?

Nasdaq’s Wild Week: Tech Titans Soar & Plunge as Volatility Spikes – What’s Next?

After a roller-coaster week, the Nasdaq Composite Index managed to finish in positive territory, showcasing resilience in the face of multiple risk flare-ups. The index closed Friday at 22,679.98 points, up 117.44 points on the dayreuters.com. All three major U.S. indices posted weekly gains, even as intraday swings tested investors’ nerves. The tech-heavy Nasdaq remains within striking distance of its record high set earlier this month, and is up roughly 15–17% for the year to datets2.tech – a strong performance reflecting 2025’s bullish momentum.
18 October 2025
·········
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Surges on Obesity Drug Boom and Alzheimer’s Breakthroughs – Is $1,000 Next?

Eli Lilly’s stock has been on a tear in 2025, powered by optimism around its new drug innovations. Shares surged dramatically at the start of October – leaping from about $726 at the end of September to as high as $832 by October 1ts2.tech. This double-digit jump in just days far outpaced the broader market and reflected euphoric sentiment toward Lilly’s growth prospectsts2.tech. Analysts attributed the rally to a perfect storm of positive news: strong recent earnings, insider buying, and fresh research fueling excitement about Lilly’s obesity and Alzheimer’s franchisests2.tech. For example, one study in late September suggested GLP-1 weight-loss drugs may significantly reduce Alzheimer’s risk, adding to the buzz around Lilly’s pipelinets2.tech.
17 October 2025
··
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly Stock Rockets on GLP‑1 Boom and New Approvals: Is LLY the Next Trillion‑Dollar Pharma Titan?

Eli Lilly and Company has become the poster‑child for the emerging class of GLP‑1‑based obesity and diabetes therapies. Its injectable tirzepatide products Mounjaro and Zepbound have delivered explosive growth, propelling the company’s market capitalization into the high‑hundred‑billion range. On 6 Oct 2025, LLY traded around $840, close to its all‑time highsmarketbeat.com. The company’s pivot toward metabolic and neurodegenerative diseases, combined with an aggressive manufacturing expansion, has made it one of the most closely watched stocks on Wall Street.
6 October 2025
·
Shutdown Drags On But Wall Street Hits Records – Here’s What’s Driving Markets

Shutdown Drags On But Wall Street Hits Records – Here’s What’s Driving Markets

Wall Street extended its rally in the face of political gridlock. Last week, the S&P 500 and Dow each rose ~1.1%, and the Nasdaq gained 1.3%, with the S&P and Dow closing at record highs on Friday reuters.com. Monday’s trading opened on a strong note as well – S&P 500 futures were up about 0.3% early in the day, on track to add to those gains reuters.com. “It certainly feels like momentum is on the side of investors over the last few days,” said Mona Mahajan, head of investment strategy at Edward Jones reuters.com. She noted that traders have been increasingly betting on Federal Reserve rate cuts as economic data softens, even with Washington in disarray. The ongoing government shutdown, now past the one-week mark, has not derailed bullish sentiment so far.
6 October 2025
····
Bitcoin Blasts Past $125K, AI Wars Escalate, and Space Tech Soars – Global Tech Roundup (Oct 5–6, 2025)

Bitcoin Blasts Past $125K, AI Wars Escalate, and Space Tech Soars – Global Tech Roundup (Oct 5–6, 2025)

OpenAI vs. Musk’s xAI – legal battle heats up: The Silicon Valley rivalry between Elon Musk and OpenAI turned into open warfare in court. Musk’s AI startup xAI sued OpenAI, accusing it of poaching staff to steal trade secrets related to xAI’s Grok chatbot. This week OpenAI hit back, asking a judge to dismiss the suit and blasting it as part of Musk’s “ongoing harassment” of the company reuters.com. OpenAI’s filing argued that “talented xAI employees are leaving in droves” under Musk and have every right to join OpenAI reuters.com. Musk, a co-founder turned critic of OpenAI, claims xAI’s tech is more advanced than ChatGPT and that OpenAI conspired with Apple to suppress rivals – allegations both Apple and OpenAI deny reuters.com. “The truth is that xAI is hemorrhaging talent to other competitors, including OpenAI,” the filing stated bluntly reuters.com. The feud has become a high-profile drama amid the red-hot AI talent race, with dueling lawsuits reflecting the skyrocketing stakes in generative AI. As one industry commentator put it, this is “CEO-speak for ‘We’re pawns in a digital Cold War’” reuters.com – the AI war is as much personal as technological.
6 October 2025
··········
U.S. Stocks Rally as Shutdown Fears Fade – Markets Hit Fresh Records

U.S. Stocks Rally as Shutdown Fears Fade – Markets Hit Fresh Records

Lara Castleton of Janus Henderson noted that Tuesday’s White House–Pfizer announcement “was the catalyst for healthcare,” freeing up investors to rotate into the beaten-down sector reuters.com. Kyle Rodda at Capital.com observed that the weak ADP report “suggests the U.S. economy is in almost dire need for further policy support,” so markets are pricing in much higher odds of Fed rate cuts in October and December reuters.com. He added that “after some initial jitters, markets shrugged off the U.S. government shutdown, at least for now,” since past shutdowns have had “trivial” market impact reuters.com.
2 October 2025
······
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Fed policy: The Fed’s Sept. 17 decision to cut rates was driven by slowing growth and job gains, though inflation has crept up federalreserve.gov. Fed Chair Powell and colleagues signaled further cuts ahead, but warned that inflation upside risks remain high federalreserve.gov reuters.com. Fed Vice Chair Bowman urged a commitment to cuts to shore up jobs reuters.com, while a strategist noted Powell was dovish but noncommittal on timing reuters.com.
28 September 2025
·············
Billion-Dollar AI Bets and Biotech Breakthroughs: Top Tech News (Sept 27–28, 2025)

Billion-Dollar AI Bets and Biotech Breakthroughs: Top Tech News (Sept 27–28, 2025)

Nvidia–OpenAI Partnership: Nvidia announced a landmark collaboration with OpenAI to deploy at least 10 gigawatts of AI computing power. Under the plan, Nvidia will invest up to $100 billion as each gigawatt of NVIDIA systems is deployed nvidianews.nvidia.com. The first 1 GW is slated for late 2026 on Nvidia’s new “Vera Rubin” supercomputer. CEO Jensen Huang said this marks “the next leap forward — deploying 10 gigawatts to power the next era of intelligence” nvidianews.nvidia.com. OpenAI’s Sam Altman emphasized that “everything starts with compute,” and the new chips will fuel AI breakthroughs. This deal comes amid massive demand for AI chips – Nvidia will continue to serve all customers, but the investment ties OpenAI and Nvidia closely together nvidianews.nvidia.com nvidianews.nvidia.com.
28 September 2025
·········
1 … 10 11 12 13
Go toTop